SciSparc & Clearmind Announce Ketamine Therapy Publication
Ticker: SPRC · Form: 6-K · Filed: Aug 29, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Aug 29, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, publication, press-release, healthcare
TL;DR
SciSparc and Clearmind published research on a new ketamine combo therapy.
AI Summary
On August 29, 2024, SciSparc Ltd. announced a collaboration with Clearmind Medicine that led to the publication of an application for an innovative ketamine-based combination therapy. This development highlights the potential of their joint research in novel therapeutic approaches.
Why It Matters
This publication signifies progress in the development of novel treatments for conditions potentially involving ketamine-based therapies, which could impact future treatment options.
Risk Assessment
Risk Level: medium — The filing is a routine report of a press release, but the underlying research involves novel therapies which carry inherent development and regulatory risks.
Key Players & Entities
- SciSparc Ltd. (company) — Registrant
- Clearmind Medicine (company) — Collaborator
- August 29, 2024 (date) — Date of press release
FAQ
What is the subject of the press release filed by SciSparc Ltd. on August 29, 2024?
The press release, titled 'SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination,' details a collaboration between SciSparc and Clearmind Medicine regarding an innovative ketamine-based combination therapy.
Which companies are involved in the collaboration mentioned in the filing?
The collaboration is between SciSparc Ltd. and Clearmind Medicine.
What type of therapy is being developed or published about?
The therapy is described as an 'innovative ketamine-based combination.'
What is the filing type and date?
The filing is a Form 6-K, filed on August 29, 2024.
What is SciSparc Ltd.'s principal executive office address?
SciSparc Ltd.'s principal executive offices are located at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel.
Filing Stats: 331 words · 1 min read · ~1 pages · Grade level 9.9 · Accepted 2024-08-29 16:30:36
Filing Documents
- ea0212832-6k_scisparc.htm (6-K) — 12KB
- ea021283201ex99-1_scisparc.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-073916.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: August 29, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3